SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (709)10/29/2004 3:59:49 PM
From: tuck   of 897
 
Glaxo is apparently going to enter the flu vaccine market next year, which won't help Chiron. Other vaccines are growing pretty slowly, except for the travel vaccines. And isn't betaseron coming off patent in a couple of years? But blood testing and other drugs seem to be growing steadily, if not mightily. They all pale in comparison to the influenza vaccine revenue being lost. Since Chiron has gotten a bad whacking, some have said it looks cheap. I'd argue that current valuation is middling at best. Mid twenties might be cheap enough.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News